What is claimed is:
1. An electronic unit device comprising:
a connector which is connectable to a to-be-connected device; and
a casing having a panel body, which includes a cut section, and a partial panel which is attachable and detachable to and from the cut section and covers at least said connector when the partial panel is attached to the cut section.
2. An electronic unit device comprising:
a casing which contains an electronic device;
a connector which is included inside said casing and connectable to a to-be-connected device; and
a cover panel which includes a panel body, which has a cut section, and a partial panel which is attachable and detachable to and from the cut section, fills the cut section with the partial panel when the partial panel is attached to the cut section, and covers at least a surface of said connector.
3. The electronic unit device according to claim 2, wherein the panel body includes one side facing the cut section and being connected to an outer wall of said casing, and can be opened and closed pivotably about the one side facing the cut section.
4. The electronic unit device according to claim 2, wherein said partial panel has a shape which corresponds to a shape of the cut section.
5. The electronic unit device according to claim 2, wherein said panel body includes a falling-prevention section for preventing said partial panel from falling from the cut section.
6. The electronic unit device according to claim 2, wherein said panel body includes a guide section which can guide the partial panel.
7. The electronic unit device according to claim 5, wherein the partial panel includes at least one engagement section which can be engaged with said falling-prevention section.
8. The electronic unit device according to claim 6, wherein the partial panel includes a section, which contacts the panel body and is so processed as to be engaged with the guide section.
9. The electronic unit device according to claim 6, wherein:
said panel body includes the cut section which is formed in a rectangular shape; and
said guide section includes a projection section or groove having substantially a same section throughout a longitudinal direction of each of facing sides of the cut section.
10. The electronic unit device according to claim 9, wherein said partial panel is formed substantially in a rectangular shape, and includes a projection section or groove having substantially a same section throughout a longitudinal direction thereof, along an edge corresponding to the guide section of the panel body.
11. The electronic unit device according to claim 7, wherein said engagement section is formed of an elastic material.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of inhibiting or treating heart damage induced by a cardiotoxic medicament in a mammal, said method comprising administering to said mammal an effective cardioprotective amount of a compound corresponding to Formula I
wherein
R1is a phenyl lower-alkyl group which may optionally be substituted in the phenyl ring by lower alkyl, lower alkoxy or halogen, or for a naphthyl lower-alkyl group,
R2 is hydrogen or a group forming a biolabile ester, and
R3 is hydrogen or a group forming a biolabile ester,
or a physiologically compatible salt thereof.
2. A method according to claim 1, wherein said medicament is a cytostatic agent.
3. A method according to claim 2, wherein said cytostatic agent is a cytostatic antibiotic.
4. A method according to claim 1, wherein said mammal is a human.
5. A method according to claim 1, wherein said mammal has suffered myocardial damage.
6. A method according to claim 1, wherein at least one of R2 and R3 is a group forming a biolabile ester.
7. A method according to claim 6, wherein the group which forms a biolabile ester is a lower alkyl group, or a phenyl or phenyl lower-alkyl group which is optionally substituted in the phenyl ring by lower alkyl or by a lower alkylene chain bonded to 2 adjacent carbon atoms.
8. A method according to claim 7, wherein the compound is (3S,2\u2032R)-3-{1-2\u2032-(ethoxycarbonyl)-4\u2032-phenyl-butyl-cyclopentane-1-carbonylamino}-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-1-acetic acid or a physiologically compatible salt thereof.
9. A method according to claim 7, wherein the group which forms a biolabile ester is a phenyl, benzyl or indanyl group or a dioxolanylmethyl group, optionally substituted in the dioxolane ring by lower alkyl.
10. A method according to claim 9, wherein the group which forms a biolabile ester is a (2,2-dimethyl-1,3-dioxolan-4-yl)methyl group or a C2-C6-alkanoyloxymethyl group, optionally substituted at the oxymethyl group by lower alkyl.
11. A method according to claim 1, wherein R2 is a group forming a biolabile ester and R3 is hydrogen.
12. In the therapeutic administration to a mammal of a substance having oxidative-cytotoxic side effects, the improvement comprising administering to said mammal an effective oxidative-cytotoxic side effect inhibiting amount of a compound corresponding to Formula I
wherein
R1 is a phenyl lower-alkyl group which may optionally be substituted in the phenyl ring by lower alkyl, lower alkoxy or halogen, or for a naphthyl lower-alkyl group,
R2 is hydrogen or a group forming a biolabile ester, and
R3 is hydrogen or a group forming a biolabile ester,
or a physiologically compatible salt thereof.
13. The improvement of claim 12, wherein said mammal is a human.
14. The improvement of claim 12, wherein said compound inhibits oxidative-cardiotoxic, side-effects.
15. The improvement of claim 12, wherein said compound or physiologically compatible salt thereof is co-administered simultaneously with said substance.
16. The improvement according to claim 12, wherein at least one of R2 and R3 is a group forming a biolabile ester.
17. The improvement according to claim 12, wherein the group which forms a biolabile ester is a lower alkyl group, or a phenyl or phenyl lower-alkyl group which is optionally substituted in the phenyl ring by lower alkyl or by a lower alkylene chain bonded to 2 adjacent carbon atoms.
18. The improvement according to claim 17, wherein the compound is (3S,2\u2032R)-3-{1-2\u2032-(ethoxycarbonyl)-4\u2032-phenyl-butyl-cyclopentane-1 -carbonylamino}-2,3,4,5-tetrahydro-2-oxo-1 H-1-benzazepin-1-acetic acid or a physiologically compatible salt thereof.
19. The improvement according to claim 17, wherein the group which forms a biolabile ester is a phenyl, benzyl or indanyl group or a dioxolanylmethyl group, optionally substituted in the dioxolane ring by lower alkyl.
20. The improvement according to claim 19, wherein the group which forms a biolabile ester is a (2,2-dimethyl-1,3-dioxolan-4-yl)methyl group or a C2-C6-alkanoyl-oxymethyl group, optionally substituted at the oxymethyl group by lower alkyl.
21. The improvement according to claim 12, wherein R2is a group forming a biolabile ester and R3 is hydrogen.
22. The improvement according to claim 12, wherein said substance is selected from the group consisting of the anthracyclines, mitoxantrone and prodrugs thereof.
23. A pharmaceutical composition according to claim 22, wherein said medicament is an anthracycline selected from the group consisting of daunorubicin, doxorubicin (adriamycin), epirubicin, and prodrugs thereof.
24. A pharmaceutical composition comprising in combination a medicament having cardiotoxic, oxidative-cytotoxic or oxidative-cardiotoxic side-effects, and a compound corresponding to Formula I
wherein
R1 is a phenyl lower-alkyl group which may optionally be substituted in the phenyl ring by lower alkyl, lower alkoxy or halogen, or for a naphthyl lower-alkyl group,
R2 is hydrogen or a group forming a biolabile ester, and
R3 is hydrogen or a group forming a biolabile ester,
or a physiologically compatible salt thereof.
25. A pharmaceutical composition according to claim 24, wherein said medicament is a cytostatic agent having cardiotoxic side-effects.
26. A pharmaceutical composition according to claim 24, wherein said medicament is a cytostatic antibiotic.
27. A pharmaceutical composition according to claim 24, wherein said medicament is selected from the group consisting of the anthracyclines, mitoxantrone and prodrugs thereof.
28. A pharmaceutical composition according to claim 27, wherein said medicament is an anthracycline selected from the group consisting of daunorubicin, doxorubicin (adriamycin), epirubicin, and prodrugs thereof.
29. A pharmaceutical composition according to claim 24, wherein at least one of R2 and R3 in said compound is a group forming a biolabile ester.
30. A pharmaceutical composition according to claim 29, wherein the group which forms a biolabile ester is a lower alkyl group, or a phenyl or phenyl lower-alkyl group which is optionally substituted in the phenyl ring by lower alkyl or by a lower alkylene chain bonded to 2 adjacent carbon atoms.
31. A pharmaceutical composition according to claim 29, wherein the compound is (3S,2\u2032R)-3-{1-2\u2032-(ethoxycarbonyl)-4\u2032-phenyl-butyl-cyclopentane-1-carbonylamino}-2,3,4,5-tetrahydro-2-oxo-1 H-1-benzazepin-1-acetic acid or a physiologically compatible salt thereof.
32. A pharmaceutical composition according to claim 29, wherein the group which forms a biolabile ester is a phenyl, benzyl or indanyl group or a dioxolanylmethyl group, optionally substituted in the dioxolane ring by lower alkyl.
33. A pharmaceutical composition according to claim 32, wherein the group which forms a biolabile ester is a (2,2-dimethyl-1,3-dioxolan-4-yl)methyl group or a C2-C6-alkanoyloxymethyl group, optionally substituted at the oxymethyl group by lower alkyl.
34. A pharmaceutical composition according to claim 24, wherein R2 in said compound is a group forming a biolabile ester and R3 is hydrogen.